TScan Therapeutics, Inc.’s TCRX share price has dipped by 5.81%, which has investors questioning if this is right time to buy ...

Granite Bio AG, a clinical-stage immunology company, has emerged from stealth with $100 million in funding. This includes a $30 million Series A led by founding investors Versant Ventures and Novartis ...

Jay Bradner, president of the Novartis Institutes for Biomedical Research (NIBR), is retiring from the position after seven years in the role, and will be replaced by Merck & Co R&D executive ...

Mosaic Therapeutics has secured the latest pieces in its combination medicine strategy by licensing two clinical stage tumor ...

Then in October the company unveiled a major restructuring of its global R&D organisation, led from its headquarters in Basel, Switzerland and the Novartis Institutes for BioMedical Research (NIBR ...

OmniAb, Inc. today announced the appointments of Philip J. Gotwals, Ph.D., and Steve Crouse to its Board of Directors. OmniAb also announced the departure of Director Sarah Boyce, who is stepping down ...

Coherus BioSciences, Inc.’s CHRS share price has dipped by 5.19%, which has investors questioning if this is right time to ...

Gotwals brings over 30 years of biopharmaceutical experience, including roles at Novartis Institutes for BioMedical Research and Biogen Idec, and currently serves as a partner at Red Sky Partners.

culminating at Novartis Institutes for BioMedical Research. As a Principal Scientist, he was an expert in molecular biology and enjoyed being part of the synthetic biology group in the global ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S. investment. The $200 billion pharma company intends to invest ...

Novartis saying on Thursday plans to spend $23 billion to build and expand 10 facilities in the US as it grapples with renewed threats of drug import duties from the Trump administration ...